Ocuphire Pharma Investor Day Presentation Deck

DR DME 20 Subject Exposure Across 11 Prior Clinical Trials Over 2000 Subject-Days of Exposure at ≥600 mg/day Total Subjects Dose: Subject-Days of Exposure Subjects with ≥21 days of exposure Subjects with >300 days of exposure 11 Trials Prior to ZETA-1 ≥600 mg/day APX3330 34* Subjects 2078 Subject-days 16 Subjects 3 Subjects <600 mg/day** APX3330 328* Subjects 17961 Subject-days 245 Subjects N/A *18 subjects in dose escalation trials received doses <600mg/day and ≥600mg/day and are included in both columns, resulting in greater than 340 subjects; **Many of the subjects between 20-240 * Eisai and Apexian Phase 1 and Phase 2 clinical trials (subject to final safety database) ** Ocuphire PHARMA

View entire presentation